Recro Pharma Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
-
51,952.00
69,337.00
71,834.00
77,347
Cost of Goods Sold (COGS) incl. D&A
1.40
-
29,938.00
39,735.00
40,776.00
45,743
Gross Income
1.40
-
22,014.00
29,602.00
31,058.00
31,604
SG&A Expense
1,088.30
11,871.80
25,298.00
46,020.00
58,521.00
76,864
EBIT
1,089.80
11,871.80
3,284.00
16,418.00
27,463.00
45,260
Unusual Expense
-
-
3,686.00
9,355.00
12,848.00
8,783
Interest Expense
868.10
4,272.90
5,560.00
5,588.00
12,034.00
8,756
Pretax Income
1,957.80
16,134.20
12,518.00
31,312.00
51,960.00
62,287
Income Tax
-
-
15,551.00
1,107.00
1,880.00
17,436
Consolidated Net Income
2,398.00
16,134.20
3,033.00
30,205.00
50,080.00
79,723
Net Income
2,398.00
16,134.20
3,033.00
30,205.00
50,080.00
79,723
Net Income After Extraordinaries
2,398.00
16,134.20
3,033.00
30,205.00
50,080.00
79,723
Net Income Available to Common
2,398.00
17,404.20
3,033.00
30,205.00
50,080.00
79,723
EPS (Basic)
0.31
2.79
0.21
2.82
2.63
3.90
Basic Shares Outstanding
7,707.60
6,238.60
8,491.00
10,721.90
19,071.00
20,465.10
EPS (Diluted)
0.31
2.79
0.21
2.82
2.63
3.90
Diluted Shares Outstanding
7,707.60
6,238.60
8,749.20
10,721.90
19,071.00
20,465.10
EBITDA
1,088.30
11,871.80
2,720.00
8,842.00
20,016.00
37,410
Non-Operating Interest Income
0.00
10.50
12.00
49.00
385.00
512
Other After Tax Income (Expense)
440.20
-
-
-
-
-
Preferred Dividends
-
1,270.10
-
-
-
-
About Recro Pharma
View Profile
